Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

Leukemia and Lymphoma

Volumn 55, Issue 9, 2014, Pages 2056-2063

  Lee, Hyun Jung ^b   Shin, Dong Hoon ^a   Kim, Kyung Bin ^b   Shin, Nari ^b   Park, Won Young ^b   Lee, Jung Hee ^b   Choi, Kyung Un ^b   Kim, Jee Yeon ^b   Lee, Chang Hun ^b   Sol, Mee Young ^b  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University   (South Korea)

Author keywords

Diffuse large B cell lymphoma; EZH2; Polycomb protein

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; TRANSCRIPTION FACTOR EZH2; VINCRISTINE; ANTINEOPLASTIC AGENT; EZH2 PROTEIN, HUMAN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; POLYCOMB REPRESSIVE COMPLEX 2; R-CHOP PROTOCOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; CANCER STAGING; GENE EXPRESSION; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MIDDLE AGED; MITOSIS; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KI-67 ANTIGEN; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MITOSIS; NEOPLASM STAGING; POLYCOMB REPRESSIVE COMPLEX 2; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84906047198     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.858816     Document Type: Article

References (18)

1. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astraYin cancer. Nat Rev Cancer 2009; 9: 773-784.
2. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 2005; 6: 838-849.
3. v an Kemenade F J, R aaphorst F M, B lokziji T, et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancYin B-cell non-Hodgkin lymphoma. Blood 2001; 97: 3896-3901.
4. Su IH, Basavaraj A, Krutchinsky AN, et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol 2003; 4: 124-131.
5. Velichutina I, Shaknovich R, Geng H, et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010; 116: 5247-5255.
6. Stein H, Warnke RA, Chan WC, et al. Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC: 2008. pp 233-237.
7. Z hi-Ming L i, J ia-Jia H uang, Y i X ia, et al. High Ki-67 expression in diffuse large B cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-chop therapy. Eur J Haematol 2012; 88: 510-517.
8. Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011; 117: 7070-7078.
9. V isco C, L i Y, X u-Monette Z Y, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012; 26: 2103-2113.
10. Hasselblom S, Ridell B, Sigurdardottir M, et al. Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Leuk Lymphoma 2008; 49: 1501-1509.
11. De Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007; 25: 805-812.
12. Liu YH, Xu FP, Zhuang HG, et al. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients. Hum Pathol 2008; 39: 875-884.
13. B racken A P, P asini D, C apra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22: 5323-5335.
14. Gonzalez ME, Li X, Yoy K, et al. Down-regulation of Enhancer of Zeste-2 decreases growth of estrogen receptor negative invasive breast carcinoma and requires BRCA1. Oncogene 2009; 28: 843-853.
15. K idani K, O saki M, T amura T, et al. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol 2009; 45: 39-46.
16. Fluge Ø, Gravdal K, Carlsen E, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer 2009; 101: 1282-1289.
17. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298-303.
18. Yap DB, Chu J, Berg T, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011; 117: 2451-2459.